HomeCompareZBH vs KLAC

ZBH vs KLAC: Dividend Comparison 2026

ZBH yields 1.08% · KLAC yields 0.55%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 KLAC wins by $774.0K in total portfolio value
10 years
ZBH
ZBH
● Live price
1.08%
Share price
$88.62
Annual div
$0.96
5Y div CAGR
0.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$21.2K
Annual income
$118.64
Full ZBH calculator →
KLAC
KLAC
● Live price
0.55%
Share price
$1,382.58
Annual div
$7.60
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$795.3K
Annual income
$589,306.66
Full KLAC calculator →

Portfolio growth — ZBH vs KLAC

📍 KLAC pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodZBHKLAC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ZBH + KLAC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ZBH pays
KLAC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ZBH
Annual income on $10K today (after 15% tax)
$92.08/yr
After 10yr DRIP, annual income (after tax)
$100.84/yr
KLAC
Annual income on $10K today (after 15% tax)
$46.72/yr
After 10yr DRIP, annual income (after tax)
$500,910.66/yr
At 15% tax rate, KLAC beats the other by $500,809.82/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ZBH + KLAC for your $10,000?

ZBH: 50%KLAC: 50%
100% KLAC50/50100% ZBH
Portfolio after 10yr
$408.2K
Annual income
$294,712.65/yr
Blended yield
72.19%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on KLAC right now

ZBH
Analyst Ratings
17
Buy
21
Hold
3
Sell
Consensus: Hold
Price Target
$105.60
+19.2% upside vs current
Range: $89.00 — $122.00
Altman Z
1.7
Piotroski
7/9
KLAC
Analyst Ratings
27
Buy
14
Hold
2
Sell
Consensus: Buy
Price Target
$1,696.31
+22.7% upside vs current
Range: $1,400.00 — $1,900.00
Altman Z
12.3
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ZBH buys
0
KLAC buys
8
PoliticianChamberTickerTypeAmountDate
Val Hoyle🏢 House$KLAC▼ Sell$1,001 - $15,0002025-09-23
Valerie Hoyle🏢 House$KLAC▲ Buy$1,001 - $15,0002025-07-28
Valerie Hoyle🏢 House$KLAC▼ Sell$1,001 - $15,0002025-04-29
William R. Keating🏢 House$KLAC▲ Buy$1,001 - $15,0002025-01-24
Gilbert Cisneros🏢 House$KLAC▼ Sell$1,001 - $15,0002025-01-13
Valerie Hoyle🏢 House$KLAC▲ Buy$1,001 - $15,0002024-10-29
John James🏢 House$KLAC▼ Sell$1,001 - $15,0002024-09-04
John James🏢 House$KLAC▼ Sell$1,001 - $15,0002024-06-26
Tommy Tuberville🏛 Senate$KLAC▼ Sell$1,001 - $15,0002024-05-03
Ro Khanna🏢 House$KLAC▲ Buy$1,001 - $15,0002024-01-10
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricZBHKLAC
Forward yield1.08%0.55%
Annual dividend / share$0.96$7.60
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0.2%100%
Portfolio after 10y$21.2K$795.3K
Annual income after 10y$118.64$589,306.66
Total dividends collected$1.1K$757.1K
Payment frequencyquarterlyquarterly
SectorHealthcareTechnology
Analyst consensusHoldBuy
Analyst price target$105.60$1,696.31

Year-by-year: ZBH vs KLAC ($10,000, DRIP)

YearZBH PortfolioZBH Income/yrKLAC PortfolioKLAC Income/yrGap
1← crossover$10,809$108.54$10,810$109.94$1.00KLAC
2$11,675$109.86$11,789$222.14$114.00KLAC
3$12,603$111.13$13,067$452.81$464.00KLAC
4$13,598$112.34$14,920$938.13$1.3KKLAC
5$14,663$113.51$17,966$2,002.14$3.3KKLAC
6$15,804$114.62$23,730$4,506.49$7.9KKLAC
7$17,026$115.69$36,517$11,125.83$19.5KKLAC
8$18,335$116.71$71,075$32,001.78$52.7KKLAC
9$19,736$117.70$192,474$116,423.57$172.7KKLAC
10$21,236$118.64$795,254$589,306.66$774.0KKLAC

ZBH vs KLAC: Complete Analysis 2026

ZBHHealthcare

Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates in the musculoskeletal healthcare business in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company designs, manufactures, and markets orthopaedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; spine products comprising medical devices and surgical instruments; and face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest toss facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest. It also offers dental products that include dental reconstructive implants, and dental prosthetic and regenerative products, as well as robotic, surgical and bone cement products. The company's products and solutions are used to treat patients suffering from disorders of, or injuries to, bones, joints, or supporting soft tissues. It serves orthopedic surgeons, neurosurgeons, oral surgeons, dentists, hospitals, stocking distributors, healthcare dealers, and other specialists, as well as agents, healthcare purchasing organizations, or buying groups. The company was formerly known as Zimmer Holdings, Inc. and changed its name to Zimmer Biomet Holdings, Inc. in June 2015. Zimmer Biomet Holdings, Inc. was founded in 1927 and is headquartered in Warsaw, Indiana.

Full ZBH Calculator →

KLACTechnology

KLA Corporation designs, manufactures, and markets process control, process-enabling, and yield management solutions for the semiconductor and related electronics industries worldwide. It operates through four segments: Semiconductor Process Control; Specialty Semiconductor Process; PCB, Display and Component Inspection; and Other. The company offers integrated circuit (IC) manufacturing products that comprises wafer inspection and review, and metrology; wafer and substrate defect inspection and metrology; reticle defect inspection and metrology; chemical/materials quality analysis; in situ process management and wafer handling diagnostics for IC and original equipment manufacturer (OEM) manufacturing; software products to provide run-time process control, defect excursion identification, process corrections, and defect classification; and refurbished and remanufactured products. It also provides specialty semiconductor manufacturing, benchtop metrology, surface characterization, and electrical property measurement services for general purpose/ lab applications; etch, plasma dicing, deposition, and other wafer processing technologies and solutions for the semiconductor and microelectronics industry. In addition, the company offers direct imaging, inspection, optical shaping, additive printing, and computer-aided manufacturing and engineering solutions for the PCB market; inspection and electrical testing systems to identify and classify defects, as well as systems to repair defects for the display market; and inspection and metrology systems for quality control and yield improvement in advanced and traditional semiconductor packaging markets. The company was formerly known as KLA-Tencor Corporation and changed its name to KLA Corporation in July 2019. KLA Corporation was incorporated in 1975 and is headquartered in Milpitas, California.

Full KLAC Calculator →
📬

Get this ZBH vs KLAC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ZBH vs SCHDZBH vs JEPIZBH vs OZBH vs KOZBH vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.